Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2012. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of March 30, 2012:
- Total Issued Ordinary Shares: 5,559,384,536 (25p each)
- Treasury Shares: 516,517,927
- Total Voting Rights: 5,042,866,609
No material changes to financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,042,866,609) for compliance with Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (516,517,927) when calculating ownership percentages.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.